FATE vs. ALLO, ADAP, CLLS, BLUE, ATRA, NMRA, VIR, BCRX, CGEM, and TARS
Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Allogene Therapeutics (ALLO), Adaptimmune Therapeutics (ADAP), Cellectis (CLLS), bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), BioCryst Pharmaceuticals (BCRX), Cullinan Therapeutics (CGEM), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
Allogene Therapeutics (NASDAQ:ALLO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Allogene Therapeutics currently has a consensus price target of $9.95, suggesting a potential upside of 298.00%. Fate Therapeutics has a consensus price target of $6.58, suggesting a potential upside of 78.89%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Fate Therapeutics.
In the previous week, Allogene Therapeutics had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 9 mentions for Allogene Therapeutics and 4 mentions for Fate Therapeutics. Allogene Therapeutics' average media sentiment score of 0.48 beat Fate Therapeutics' score of 0.30 indicating that Fate Therapeutics is being referred to more favorably in the news media.
83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 24.3% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Allogene Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
Fate Therapeutics received 208 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 68.62% of users gave Fate Therapeutics an outperform vote while only 64.83% of users gave Allogene Therapeutics an outperform vote.
Fate Therapeutics has higher revenue and earnings than Allogene Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fate Therapeutics has a net margin of -2,933.79% compared to Fate Therapeutics' net margin of -223,139.98%. Allogene Therapeutics' return on equity of -46.49% beat Fate Therapeutics' return on equity.
Summary
Fate Therapeutics beats Allogene Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Fate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fate Therapeutics Competitors List
Related Companies and Tools
